Defining Synchronous Oligometastatic Non–Small Cell Lung Cancer: A Systematic Review
Synchronous oligometastatic (sOM) disease is an oncological concept characterized by a limited cancer burden. Patients with oligometastasis could potentially benefit from local radical treatments. Despite the fact that the sOM condition is well recognized, a universal definition, including a specifi...
Saved in:
| Published in | Journal of thoracic oncology Vol. 14; no. 12; pp. 2053 - 2061 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.12.2019
Copyright by the International Association for the Study of Lung Cancer Lippincott, Williams & Wilkins |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Synchronous oligometastatic (sOM) disease is an oncological concept characterized by a limited cancer burden. Patients with oligometastasis could potentially benefit from local radical treatments. Despite the fact that the sOM condition is well recognized, a universal definition, including a specific definition for NSCLC, is not yet available. The aim of this systematic review was to summarize the definitions of and staging requirements for use of the term synchronous oligometastatic in the context of NSCLC.
The key issue was formulated in one research question according to the population, intervention, comparator, and outcomes strategy. The question was introduced in MEDLINE (OvidSP). All articles dealing with sOM NSCLC and providing a definition of synchronous oligometastasis in NSCLC were selected and analyzed.
A total of 21 eligible articles focusing on sOM NSCLC were retrieved and analyzed. In 17 studies (81%), patients had to be staged with magnetic resonance imaging or computed tomography of the brain, thoracic and abdominal computed tomography, and positron emission tomography. The total number of metastases allowed in the definitions ranged from one to eight, but in 38.1% of studies the maximum number was 5. Most of the publications did not define the number of involved organs or the maximum number of metastases per organ. For mediastinal lymph node involvement, only five articles (27.8%) counted this as a metastatic site.
No uniform definition of sOM NSCLC could be retrieved by this systematic review. However, extended staging was mandated in most of the studies. An accepted oncological definition of synchronous oligometastasis is essential for patient selection to define prospective clinical trials. |
|---|---|
| AbstractList | Synchronous oligometastatic (sOM) disease is an oncological concept characterized by a limited cancer burden. Patients with oligometastasis could potentially benefit from local radical treatments. Despite the fact that the sOM condition is well recognized, a universal definition, including a specific definition for NSCLC, is not yet available. The aim of this systematic review was to summarize the definitions of and staging requirements for use of the term synchronous oligometastatic in the context of NSCLC.
The key issue was formulated in one research question according to the population, intervention, comparator, and outcomes strategy. The question was introduced in MEDLINE (OvidSP). All articles dealing with sOM NSCLC and providing a definition of synchronous oligometastasis in NSCLC were selected and analyzed.
A total of 21 eligible articles focusing on sOM NSCLC were retrieved and analyzed. In 17 studies (81%), patients had to be staged with magnetic resonance imaging or computed tomography of the brain, thoracic and abdominal computed tomography, and positron emission tomography. The total number of metastases allowed in the definitions ranged from one to eight, but in 38.1% of studies the maximum number was 5. Most of the publications did not define the number of involved organs or the maximum number of metastases per organ. For mediastinal lymph node involvement, only five articles (27.8%) counted this as a metastatic site.
No uniform definition of sOM NSCLC could be retrieved by this systematic review. However, extended staging was mandated in most of the studies. An accepted oncological definition of synchronous oligometastasis is essential for patient selection to define prospective clinical trials. INTRODUCTION:Synchronous oligometastatic (sOM) disease is an oncological concept characterized by a limited cancer burden. Patients with oligometastasis could potentially benefit from local radical treatments. Despite the fact that the sOM condition is well recognized, a universal definition, including a specific definition for NSCLC, is not yet available. The aim of this systematic review was to summarize the definitions of and staging requirements for use of the term synchronous oligometastatic in the context of NSCLC. METHODS:The key issue was formulated in one research question according to the population, intervention, comparator, and outcomes strategy. The question was introduced in MEDLINE (OvidSP). All articles dealing with sOM NSCLC and providing a definition of synchronous oligometastasis in NSCLC were selected and analyzed. RESULTS:A total of 21 eligible articles focusing on sOM NSCLC were retrieved and analyzed. In 17 studies (81%), patients had to be staged with magnetic resonance imaging or computed tomography of the brain, thoracic and abdominal computed tomography, and positron emission tomography. The total number of metastases allowed in the definitions ranged from one to eight, but in 38.1% of studies the maximum number was 5. Most of the publications did not define the number of involved organs or the maximum number of metastases per organ. For mediastinal lymph node involvement, only five articles (27.8%) counted this as a metastatic site. CONCLUSIONS:No uniform definition of sOM NSCLC could be retrieved by this systematic review. However, extended staging was mandated in most of the studies. An accepted oncological definition of synchronous oligometastasis is essential for patient selection to define prospective clinical trials. Introduction: Synchronous oligometastatic (sOM) disease is an oncological concept characterized by a limited cancer burden. Patients with oligometastasis could potentially benefit from local radical treatments. Despite the fact that the sOM condition is well recognized, a universal definition, including a specific definition for NSCLC, is not yet available. The aim of this systematic review was to summarize the definitions of and staging requirements for use of the term synchronous oligometastatic in the context of NSCLC.Methods: The key issue was formulated in one research question according to the population, intervention, comparator, and outcomes strategy. The question was introduced in MEDLINE (OvidSP). All articles dealing with sOM NSCLC and providing a definition of synchronous oligometastasis in NSCLC were selected and analyzed.Results: A total of 21 eligible articles focusing on sOM NSCLC were retrieved and analyzed. In 17 studies (81%), patients had to be staged with magnetic resonance imaging or computed tomography of the brain, thoracic and abdominal computed tomography, and positron emission tomography. The total number of metastases allowed in the definitions ranged from one to eight, but in 38.1% of studies the maximum number was 5. Most of the publications did not define the number of involved organs or the maximum number of metastases per organ. For mediastinal lymph node involvement, only five articles (27.8%) counted this as a metastatic site.Conclusions: No uniform definition of sOM NSCLC could be retrieved by this systematic review. However, extended staging was mandated in most of the studies. An accepted oncological definition of synchronous oligometastasis is essential for patient selection to define prospective clinical trials. Synchronous oligometastatic (sOM) disease is an oncological concept characterized by a limited cancer burden. Patients with oligometastasis could potentially benefit from local radical treatments. Despite the fact that the sOM condition is well recognized, a universal definition, including a specific definition for NSCLC, is not yet available. The aim of this systematic review was to summarize the definitions of and staging requirements for use of the term synchronous oligometastatic in the context of NSCLC.INTRODUCTIONSynchronous oligometastatic (sOM) disease is an oncological concept characterized by a limited cancer burden. Patients with oligometastasis could potentially benefit from local radical treatments. Despite the fact that the sOM condition is well recognized, a universal definition, including a specific definition for NSCLC, is not yet available. The aim of this systematic review was to summarize the definitions of and staging requirements for use of the term synchronous oligometastatic in the context of NSCLC.The key issue was formulated in one research question according to the population, intervention, comparator, and outcomes strategy. The question was introduced in MEDLINE (OvidSP). All articles dealing with sOM NSCLC and providing a definition of synchronous oligometastasis in NSCLC were selected and analyzed.METHODSThe key issue was formulated in one research question according to the population, intervention, comparator, and outcomes strategy. The question was introduced in MEDLINE (OvidSP). All articles dealing with sOM NSCLC and providing a definition of synchronous oligometastasis in NSCLC were selected and analyzed.A total of 21 eligible articles focusing on sOM NSCLC were retrieved and analyzed. In 17 studies (81%), patients had to be staged with magnetic resonance imaging or computed tomography of the brain, thoracic and abdominal computed tomography, and positron emission tomography. The total number of metastases allowed in the definitions ranged from one to eight, but in 38.1% of studies the maximum number was 5. Most of the publications did not define the number of involved organs or the maximum number of metastases per organ. For mediastinal lymph node involvement, only five articles (27.8%) counted this as a metastatic site.RESULTSA total of 21 eligible articles focusing on sOM NSCLC were retrieved and analyzed. In 17 studies (81%), patients had to be staged with magnetic resonance imaging or computed tomography of the brain, thoracic and abdominal computed tomography, and positron emission tomography. The total number of metastases allowed in the definitions ranged from one to eight, but in 38.1% of studies the maximum number was 5. Most of the publications did not define the number of involved organs or the maximum number of metastases per organ. For mediastinal lymph node involvement, only five articles (27.8%) counted this as a metastatic site.No uniform definition of sOM NSCLC could be retrieved by this systematic review. However, extended staging was mandated in most of the studies. An accepted oncological definition of synchronous oligometastasis is essential for patient selection to define prospective clinical trials.CONCLUSIONSNo uniform definition of sOM NSCLC could be retrieved by this systematic review. However, extended staging was mandated in most of the studies. An accepted oncological definition of synchronous oligometastasis is essential for patient selection to define prospective clinical trials. |
| Author | Novello, Silvia Dingemans, Anne-Marie C. Giaj-Levra, Niccolò Besse, Benjamin Hasan, Baktiar Berghmans, Thierry Levy, Antonin Giaj-Levra, Matteo Durieux, Valerie Hendriks, Lizza E. |
| AuthorAffiliation | Department of Cancer Medecine, Gustave Roussy, Institut d’Oncologie Thoracique, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France European Organization for Research and Treatment of Cancer, Brussels, Belgium Department of Intensive Care and Oncological Emergencies and Thoracic Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium Department of Pulmonary Diseases, GROW–School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands Bibliothèque des Sciences de la Santé, Université Libre de Bruxelles, Bruxelles, Belgium Oncology Department, University of Turin, AOU San Luigi, Orbassano, Italy |
| AuthorAffiliation_xml | – name: Department of Pulmonary Diseases, GROW–School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands – name: Bibliothèque des Sciences de la Santé, Université Libre de Bruxelles, Bruxelles, Belgium – name: European Organization for Research and Treatment of Cancer, Brussels, Belgium – name: Oncology Department, University of Turin, AOU San Luigi, Orbassano, Italy – name: Department of Intensive Care and Oncological Emergencies and Thoracic Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium – name: Department of Cancer Medecine, Gustave Roussy, Institut d’Oncologie Thoracique, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France |
| Author_xml | – sequence: 1 givenname: Niccolò surname: Giaj-Levra fullname: Giaj-Levra, Niccolò organization: Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy – sequence: 2 givenname: Matteo surname: Giaj-Levra fullname: Giaj-Levra, Matteo email: mgiajleva@chu-grenoble.fr organization: Young Investigators European Organization for Research and Treatment of Cancer Lung Cancer Group, Brussels, Belgium – sequence: 3 givenname: Valerie surname: Durieux fullname: Durieux, Valerie organization: Bibliothèque des Sciences de la Santé, Université Libre de Bruxelles, Bruxelles, Belgium – sequence: 4 givenname: Silvia surname: Novello fullname: Novello, Silvia organization: Oncology Department, University of Turin, AOU San Luigi, Orbassano, Italy – sequence: 5 givenname: Benjamin surname: Besse fullname: Besse, Benjamin organization: Department of Cancer Medecine, Gustave Roussy, Institut d’Oncologie Thoracique, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France – sequence: 6 givenname: Baktiar surname: Hasan fullname: Hasan, Baktiar organization: European Organization for Research and Treatment of Cancer, Brussels, Belgium – sequence: 7 givenname: Lizza E. surname: Hendriks fullname: Hendriks, Lizza E. organization: Young Investigators European Organization for Research and Treatment of Cancer Lung Cancer Group, Brussels, Belgium – sequence: 8 givenname: Antonin surname: Levy fullname: Levy, Antonin organization: Young Investigators European Organization for Research and Treatment of Cancer Lung Cancer Group, Brussels, Belgium – sequence: 9 givenname: Anne-Marie C. surname: Dingemans fullname: Dingemans, Anne-Marie C. organization: Department of Pulmonary Diseases, GROW–School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands – sequence: 10 givenname: Thierry surname: Berghmans fullname: Berghmans, Thierry organization: Department of Intensive Care and Oncological Emergencies and Thoracic Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31195177$$D View this record in MEDLINE/PubMed https://hal.science/hal-03489080$$DView record in HAL |
| BookMark | eNp9kctu1DAUhiNURC_wAixQlrBIOI6dxEZsRsOlSCMqUWBrOfFJ4yGJW9vTUXe8A2_Ik-CQoQsWleWLrO-zj_2fJkeTnTBJnhPICZDq9Tbfht7mBRCRQ5kDrR8lJ6Qsq4xQDkeHNfCKHSen3m8BWAmMP0mOKSGiJHV9knx_h52ZzHSVXt5Nbe_sZHc-vRjMlR0xKB9UMG362U6_f_66HNUwpGuMw2YXjbWaWnRv0lV0fcDxL_oFbw3unyaPOzV4fHaYz5JvH95_XZ9nm4uPn9arTdayWsQ6taaxVV3RKd4oQRinoAuBjCtWipqXWnSdAlqBwEazmhDaEaIFrZsSdUPPklfLub0a5LUzo3J30iojz1cbOe8BZVwAh1sS2ZcLe-3szQ59kKPxbXyNmjA-WhZFRSnlouQRfXFAd82I-v7kf_8WgWIBWme9d9jdIwTkHI7cyjkcOYcjoYx1zBL_T2rN_L92Ck6Z4WGVLereDgGd_zHs9uhkj2oIvQRSsFg4y2aFFACQxQ5V1N4uGsYMYi5O-tZgTE0bh22Q2pqHbv0DrHS5ig |
| CitedBy_id | crossref_primary_10_37349_etat_2024_00228 crossref_primary_10_3390_cancers14051350 crossref_primary_10_1259_bjr_20220035 crossref_primary_10_1016_S1470_2045_23_00286_3 crossref_primary_10_1016_j_cllc_2020_10_019 crossref_primary_10_1097_MNM_0000000000001599 crossref_primary_10_1016_j_ctro_2023_100637 crossref_primary_10_1016_j_ccm_2020_02_004 crossref_primary_10_1016_j_ejca_2023_112947 crossref_primary_10_4274_uob_galenos_2024_2024_7_2 crossref_primary_10_1007_s11748_020_01568_z crossref_primary_10_1183_13993003_01336_2022 crossref_primary_10_1093_ejcts_ezae217 crossref_primary_10_1016_j_ejca_2019_09_012 crossref_primary_10_3390_cancers13246374 crossref_primary_10_1016_j_ejca_2019_09_013 crossref_primary_10_1186_s12885_021_08851_z crossref_primary_10_1177_15330338211033064 crossref_primary_10_3390_cancers15051571 crossref_primary_10_1016_j_eururo_2023_05_005 crossref_primary_10_1016_j_chest_2020_04_042 crossref_primary_10_1111_cas_14707 crossref_primary_10_1186_s12885_020_07055_1 crossref_primary_10_1016_j_jtho_2024_01_019 crossref_primary_10_1016_j_rmr_2023_07_002 crossref_primary_10_1016_j_lungcan_2019_11_005 crossref_primary_10_2482_haigan_61_95 crossref_primary_10_1016_j_jtocrr_2025_100790 crossref_primary_10_1016_j_canrad_2021_06_011 crossref_primary_10_1016_j_thorsurg_2024_11_009 crossref_primary_10_1186_s12885_025_13478_5 crossref_primary_10_3390_cancers16010230 crossref_primary_10_1002_ijc_35199 crossref_primary_10_1016_j_jtho_2019_10_008 crossref_primary_10_1016_j_lungcan_2020_12_029 crossref_primary_10_1186_s12885_022_09245_5 crossref_primary_10_1016_j_radonc_2020_04_003 crossref_primary_10_1016_j_athoracsur_2021_04_057 crossref_primary_10_1200_JCO_23_02075 |
| Cites_doi | 10.21037/atm.2018.01.25 10.1016/j.athoracsur.2016.04.086 10.1159/000365634 10.1093/jjco/hyq044 10.1016/j.jtho.2018.08.529 10.1016/S0169-5002(02)00183-6 10.1016/j.radonc.2006.09.006 10.1016/S1470-2045(16)30532-0 10.1016/j.ijrobp.2015.08.012 10.1186/1748-717X-6-80 10.1016/j.ijrobp.2014.04.007 10.1016/j.jtho.2015.09.009 10.1200/JCO.1995.13.1.8 10.1016/j.jtho.2018.08.531 10.1016/j.jtcvs.2012.05.051 10.1186/s12885-016-2952-3 10.1001/jamaoncol.2017.3501 10.1186/s12885-016-2379-x 10.1007/s12262-012-0771-6 10.1097/JTO.0b013e318262caf6 10.1016/j.lungcan.2013.07.023 10.1093/annonc/mdy275 10.1016/j.ijrobp.2012.02.054 10.1016/j.ijrobp.2014.07.012 10.1016/j.prro.2014.11.006 10.1111/1759-7714.12386 10.1016/j.ejca.2017.12.012 10.1016/j.jtho.2018.08.530 10.1016/j.lungcan.2012.09.011 10.21037/jtd.2017.06.133 |
| ContentType | Journal Article |
| Copyright | 2019 International Association for the Study of Lung Cancer Copyright © 2019 by the International Association for the Study of Lung Cancer Copyright © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. Attribution - NonCommercial |
| Copyright_xml | – notice: 2019 International Association for the Study of Lung Cancer – notice: Copyright © 2019 by the International Association for the Study of Lung Cancer – notice: Copyright © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. – notice: Attribution - NonCommercial |
| CorporateAuthor | European Organization for Research and Treatment of Cancer-Lung Cancer Group |
| CorporateAuthor_xml | – name: European Organization for Research and Treatment of Cancer-Lung Cancer Group |
| DBID | AAYXX CITATION NPM 7X8 1XC VOOES |
| DOI | 10.1016/j.jtho.2019.05.037 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1556-1380 |
| EndPage | 2061 |
| ExternalDocumentID | oai_HAL_hal_03489080v1 31195177 10_1016_j_jtho_2019_05_037 01243894-201912000-00006 S1556086419304587 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GrantInformation_xml | – fundername: Lilly funderid: https://doi.org/10.13039/100004312 – fundername: Sanofi funderid: https://doi.org/10.13039/100004339 – fundername: Roche funderid: https://doi.org/10.13039/100004337 – fundername: Biogen funderid: https://doi.org/10.13039/100005614 – fundername: Novartis funderid: https://doi.org/10.13039/100004336 – fundername: Spectrum Pharmaceuticals funderid: https://doi.org/10.13039/100006399 – fundername: AbbVie funderid: https://doi.org/10.13039/100006483 – fundername: AstraZeneca funderid: https://doi.org/10.13039/100004325 – fundername: Pfizer funderid: https://doi.org/10.13039/100004319 – fundername: Celgene funderid: https://doi.org/10.13039/100006436 |
| GroupedDBID | --- .55 .XZ .Z2 0R~ 457 53G 5GY 5VS 6I. 9UZ AACTN AAEDW AAFTH AAIAV AAKAS AALRI AAWTL AAXUO ABBUW ABJNI ABMAC ABPMR ABVKL ACDDN ACGFS ACWDW ACWRI ADBBV ADBIZ ADEZE ADZCM AE3 AENEX AEXQZ AFTJW AFTRI AGHFR AHPSJ AITUG AIZYK ALMA_UNASSIGNED_HOLDINGS AMRAJ AWKKM BOYCO C45 CS3 DU5 E.X EBS EJD EX3 F5P FDB FL- HZ~ IN~ KD2 NCXOZ NTWIH O9- OFXIZ OGEVE OK1 OVD P2P ROL S4S SSZ TEORI V2I W3M WOQ WOW X7M AAYWO ADVLN AFETI AFJKZ AGCQF AKRWK APXCP AAYXX ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP CITATION NPM 7X8 1XC VOOES |
| ID | FETCH-LOGICAL-c4796-1dd3d3d6f2fa8ba914830d29e48a459785d9ffa03609ebd47113f11d937b5edb3 |
| ISSN | 1556-0864 1556-1380 |
| IngestDate | Fri May 09 12:15:29 EDT 2025 Thu Jul 10 22:08:13 EDT 2025 Thu Apr 03 07:01:37 EDT 2025 Tue Jul 01 02:56:55 EDT 2025 Thu Apr 24 22:56:45 EDT 2025 Fri May 16 03:41:39 EDT 2025 Fri Feb 23 02:15:01 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | Synchronous Systematic review NSCLC Oligometastatic disease definition |
| Language | English |
| License | Copyright © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. Attribution - NonCommercial: http://creativecommons.org/licenses/by-nc |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c4796-1dd3d3d6f2fa8ba914830d29e48a459785d9ffa03609ebd47113f11d937b5edb3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://hal.science/hal-03489080 |
| PMID | 31195177 |
| PQID | 2263338958 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | hal_primary_oai_HAL_hal_03489080v1 proquest_miscellaneous_2263338958 pubmed_primary_31195177 crossref_primary_10_1016_j_jtho_2019_05_037 crossref_citationtrail_10_1016_j_jtho_2019_05_037 wolterskluwer_health_01243894-201912000-00006 elsevier_sciencedirect_doi_10_1016_j_jtho_2019_05_037 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-December |
| PublicationDateYYYYMMDD | 2019-12-01 |
| PublicationDate_xml | – month: 12 year: 2019 text: 2019-December |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of thoracic oncology |
| PublicationTitleAlternate | J Thorac Oncol |
| PublicationYear | 2019 |
| Publisher | Elsevier Inc Copyright by the International Association for the Study of Lung Cancer Lippincott, Williams & Wilkins |
| Publisher_xml | – name: Elsevier Inc – name: Copyright by the International Association for the Study of Lung Cancer – name: Lippincott, Williams & Wilkins |
| References | Lopez Guerra, Gomez, Zhuang (bib13) 2012; 84 Inoue, Katoh, Aoyama (bib22) 2010; 40 Goldstraw, Chansky, Crowley (bib10) 2016; 11 Khan, Mehta, Zusag (bib12) 2006; 81 Planchard, Popat, Kerr (bib1) 2018; 29 Ricardi, Giaj Levra, Badellino, Alongi (bib3) 2017; 9 Johnson, Rosen, Salazar, Boffa (bib11) 2016; 102 Collaud, Stahel, Inci (bib24) 2012; 78 Nieder, Tollåli, Reigstad, Pawinski, Haukland, Dalhaug (bib14) 2014; 23 Hendriks, Dooms, Berghmans (bib9) 2018; 13 National Comprehensive Cancer Network. Non-small cell lung cancer (version 3.2018). Accessed December 16, 2018. Gomez, Blumenschein, Lee (bib6) 2016; 17 Fleckenstein, Petroff, Schäfers, Wehler, Schöpe (bib29) 2016; 16 Iyengar, Wardak, Gerber (bib5) 2018; 4 Levy, Hendriks, Berghmans (bib7) 2018; 13 Plönes, Osei-Agyemang, Krohn, Passlick (bib16) 2015; 77 Su, Li, Lu (bib20) 2015; 93 Volpi, Ali, Tasker, Peryt, Aresu, Coonar (bib31) 2018; 6 Xanthopoulos, Handorf, Simone (bib21) 2015; 5 Parikh, Cronin, Kozono (bib15) 2014; 89 deSouza, Liu, Chiti (bib30) 2018; 91 Hellman, Weichselbaum (bib2) 1995; 13 Su, Hu, Ouyang (bib19) 2016; 16 Griffioen, Toguri, Dahele (bib28) 2013; 82 Cheruvu, Metcalfe, Metcalfe, Chen, Okunieff, Milano (bib23) 2011; 6 Dingemans, Hendriks, Berghmans (bib8) 2018; 13 Downey, Ng, Kris (bib27) 2002; 38 Sakai, Takeda, Hayashi (bib17) 2016; 7 De Ruysscher, Wanders, van Baardwijk (bib26) 2012; 7 Congedo, Cesario, Lococo (bib25) 2012; 144 Sheu, Heymach, Swisher (bib18) 2014; 90 Planchard (10.1016/j.jtho.2019.05.037_bib1) 2018; 29 Goldstraw (10.1016/j.jtho.2019.05.037_bib10) 2016; 11 Hellman (10.1016/j.jtho.2019.05.037_bib2) 1995; 13 Fleckenstein (10.1016/j.jtho.2019.05.037_bib29) 2016; 16 Khan (10.1016/j.jtho.2019.05.037_bib12) 2006; 81 Parikh (10.1016/j.jtho.2019.05.037_bib15) 2014; 89 Johnson (10.1016/j.jtho.2019.05.037_bib11) 2016; 102 Downey (10.1016/j.jtho.2019.05.037_bib27) 2002; 38 Volpi (10.1016/j.jtho.2019.05.037_bib31) 2018; 6 Xanthopoulos (10.1016/j.jtho.2019.05.037_bib21) 2015; 5 Collaud (10.1016/j.jtho.2019.05.037_bib24) 2012; 78 Su (10.1016/j.jtho.2019.05.037_bib20) 2015; 93 Dingemans (10.1016/j.jtho.2019.05.037_bib8) 2018; 13 Griffioen (10.1016/j.jtho.2019.05.037_bib28) 2013; 82 Levy (10.1016/j.jtho.2019.05.037_bib7) 2018; 13 Plönes (10.1016/j.jtho.2019.05.037_bib16) 2015; 77 Sakai (10.1016/j.jtho.2019.05.037_bib17) 2016; 7 De Ruysscher (10.1016/j.jtho.2019.05.037_bib26) 2012; 7 Su (10.1016/j.jtho.2019.05.037_bib19) 2016; 16 Nieder (10.1016/j.jtho.2019.05.037_bib14) 2014; 23 Inoue (10.1016/j.jtho.2019.05.037_bib22) 2010; 40 Congedo (10.1016/j.jtho.2019.05.037_bib25) 2012; 144 deSouza (10.1016/j.jtho.2019.05.037_bib30) 2018; 91 Iyengar (10.1016/j.jtho.2019.05.037_bib5) 2018; 4 Cheruvu (10.1016/j.jtho.2019.05.037_bib23) 2011; 6 Sheu (10.1016/j.jtho.2019.05.037_bib18) 2014; 90 10.1016/j.jtho.2019.05.037_bib4 Lopez Guerra (10.1016/j.jtho.2019.05.037_bib13) 2012; 84 Hendriks (10.1016/j.jtho.2019.05.037_bib9) 2018; 13 Ricardi (10.1016/j.jtho.2019.05.037_bib3) 2017; 9 Gomez (10.1016/j.jtho.2019.05.037_bib6) 2016; 17 31757373 - J Thorac Oncol. 2019 Dec;14(12):2042-2045 |
| References_xml | – volume: 9 start-page: 2235 year: 2017 end-page: 2237 ident: bib3 article-title: Role of consolidative stereotactic ablative radiotherapy in patients with oligometastatic non-small cell lung cancer publication-title: J Thorac Dis – volume: 5 start-page: e355 year: 2015 end-page: e363 ident: bib21 article-title: Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung cancer: a hypothesis-generating study publication-title: Pract Radiat Oncol – volume: 29 start-page: iv192 year: 2018 end-page: iv237 ident: bib1 article-title: Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol – volume: 38 start-page: 193 year: 2002 end-page: 197 ident: bib27 article-title: A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis publication-title: Lung Cancer – volume: 78 start-page: 234 year: 2012 end-page: 238 ident: bib24 article-title: Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage publication-title: Lung Cancer Amst Neth – volume: 13 start-page: 8 year: 1995 end-page: 10 ident: bib2 article-title: Oligometastases publication-title: J Clin Oncol – volume: 4 year: 2018 ident: bib5 article-title: Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial publication-title: JAMA Oncol – volume: 13 start-page: S446 year: 2018 end-page: S447 ident: bib9 article-title: MA25.03 Defining oligometastatic non-small cell lung cancer (NSCLC): an evolving multidisciplinary expert opinion publication-title: J Thorac Oncol – volume: 82 start-page: 95 year: 2013 end-page: 102 ident: bib28 article-title: Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors publication-title: Lung Cancer – volume: 102 start-page: 1166 year: 2016 end-page: 1171 ident: bib11 article-title: Outcomes of a highly selective surgical approach to oligometastatic lung cancer publication-title: Ann Thorac Surg – volume: 16 start-page: 348 year: 2016 ident: bib29 article-title: Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer publication-title: BMC Cancer – volume: 90 start-page: 850 year: 2014 end-page: 857 ident: bib18 article-title: Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy publication-title: Int J Radiat Oncol Biol Phys – volume: 91 start-page: 153 year: 2018 end-page: 163 ident: bib30 article-title: Strategies and technical challenges for imaging oligometastatic disease: recommendations from the European Organisation for Research and Treatment of Cancer imaging group publication-title: Eur J Cancer – volume: 6 start-page: 80 year: 2011 ident: bib23 article-title: Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer publication-title: Radiat Oncol – volume: 84 start-page: e61 year: 2012 end-page: e67 ident: bib13 article-title: Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis publication-title: Int J Radiat Oncol Biol Phys – volume: 77 start-page: 216 year: 2015 end-page: 220 ident: bib16 article-title: Surgical treatment of extrapulmonary oligometastatic non-small cell lung cancer publication-title: Indian J Surg – volume: 40 start-page: 788 year: 2010 end-page: 794 ident: bib22 article-title: Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions publication-title: Jpn J Clin Oncol – volume: 144 start-page: 444 year: 2012 end-page: 452 ident: bib25 article-title: Surgery for oligometastatic non-small cell lung cancer: long-term results from a single center experience publication-title: J Thorac Cardiovasc Surg – volume: 7 start-page: 670 year: 2016 end-page: 675 ident: bib17 article-title: Clinical outcome of node-negative oligometastatic non-small cell lung cancer publication-title: Thorac Cancer – volume: 93 start-page: 769 year: 2015 end-page: 777 ident: bib20 article-title: Three-dimensional radiation therapy to the primary tumor with concurrent chemotherapy in patients with stage IV non-small cell lung cancer: results of a multicenter phase 2 study from PPRA-RTOG, China publication-title: Int J Radiat Oncol Biol Phys – reference: National Comprehensive Cancer Network. Non-small cell lung cancer (version 3.2018). Accessed December 16, 2018. – volume: 89 start-page: 880 year: 2014 end-page: 887 ident: bib15 article-title: Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer publication-title: Int J Radiat Oncol Biol Phys – volume: 7 start-page: 1547 year: 2012 end-page: 1555 ident: bib26 article-title: Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450) publication-title: J Thorac Oncol – volume: 13 start-page: S446 year: 2018 ident: bib8 article-title: MA25.02 Searching for a definition of synchronous oligometastatic (sOM)-NSCLC: a consensus from thoracic oncology experts publication-title: J Thorac Oncol – volume: 11 start-page: 39 year: 2016 end-page: 51 ident: bib10 article-title: The IASLC Lung Cancer Staging Project: proposals for revision of the TNM Stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer publication-title: J Thorac Oncol – volume: 17 start-page: 1672 year: 2016 end-page: 1682 ident: bib6 article-title: Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study publication-title: Lancet Oncol – volume: 16 start-page: 908 year: 2016 ident: bib19 article-title: Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies publication-title: BMC Cancer – volume: 13 start-page: S445 year: 2018 end-page: S446 ident: bib7 article-title: MA25.01 EORTC Lung Cancer Group survey to define synchronous oligometastatic disease in NSCLC publication-title: J Thorac Oncol – volume: 23 start-page: 526 year: 2014 end-page: 531 ident: bib14 article-title: Oligometastatic non-small cell lung cancer: a significant entity outside of specialized cancer centers? publication-title: Med Princ Pract – volume: 6 start-page: 95 year: 2018 ident: bib31 article-title: The role of positron emission tomography in the diagnosis, staging and response assessment of non-small cell lung cancer publication-title: Ann Transl Med – volume: 81 start-page: 163 year: 2006 end-page: 167 ident: bib12 article-title: Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC) publication-title: Radiother Oncol – volume: 6 start-page: 95 year: 2018 ident: 10.1016/j.jtho.2019.05.037_bib31 article-title: The role of positron emission tomography in the diagnosis, staging and response assessment of non-small cell lung cancer publication-title: Ann Transl Med doi: 10.21037/atm.2018.01.25 – volume: 102 start-page: 1166 year: 2016 ident: 10.1016/j.jtho.2019.05.037_bib11 article-title: Outcomes of a highly selective surgical approach to oligometastatic lung cancer publication-title: Ann Thorac Surg doi: 10.1016/j.athoracsur.2016.04.086 – volume: 23 start-page: 526 year: 2014 ident: 10.1016/j.jtho.2019.05.037_bib14 article-title: Oligometastatic non-small cell lung cancer: a significant entity outside of specialized cancer centers? publication-title: Med Princ Pract doi: 10.1159/000365634 – volume: 40 start-page: 788 year: 2010 ident: 10.1016/j.jtho.2019.05.037_bib22 article-title: Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions publication-title: Jpn J Clin Oncol doi: 10.1093/jjco/hyq044 – volume: 13 start-page: S445 year: 2018 ident: 10.1016/j.jtho.2019.05.037_bib7 article-title: MA25.01 EORTC Lung Cancer Group survey to define synchronous oligometastatic disease in NSCLC publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2018.08.529 – volume: 38 start-page: 193 year: 2002 ident: 10.1016/j.jtho.2019.05.037_bib27 article-title: A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis publication-title: Lung Cancer doi: 10.1016/S0169-5002(02)00183-6 – volume: 81 start-page: 163 year: 2006 ident: 10.1016/j.jtho.2019.05.037_bib12 article-title: Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC) publication-title: Radiother Oncol doi: 10.1016/j.radonc.2006.09.006 – volume: 17 start-page: 1672 year: 2016 ident: 10.1016/j.jtho.2019.05.037_bib6 article-title: Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30532-0 – volume: 93 start-page: 769 year: 2015 ident: 10.1016/j.jtho.2019.05.037_bib20 article-title: Three-dimensional radiation therapy to the primary tumor with concurrent chemotherapy in patients with stage IV non-small cell lung cancer: results of a multicenter phase 2 study from PPRA-RTOG, China publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2015.08.012 – volume: 6 start-page: 80 year: 2011 ident: 10.1016/j.jtho.2019.05.037_bib23 article-title: Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer publication-title: Radiat Oncol doi: 10.1186/1748-717X-6-80 – volume: 89 start-page: 880 year: 2014 ident: 10.1016/j.jtho.2019.05.037_bib15 article-title: Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2014.04.007 – volume: 11 start-page: 39 year: 2016 ident: 10.1016/j.jtho.2019.05.037_bib10 article-title: The IASLC Lung Cancer Staging Project: proposals for revision of the TNM Stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2015.09.009 – volume: 13 start-page: 8 year: 1995 ident: 10.1016/j.jtho.2019.05.037_bib2 article-title: Oligometastases publication-title: J Clin Oncol doi: 10.1200/JCO.1995.13.1.8 – volume: 13 start-page: S446 year: 2018 ident: 10.1016/j.jtho.2019.05.037_bib9 article-title: MA25.03 Defining oligometastatic non-small cell lung cancer (NSCLC): an evolving multidisciplinary expert opinion publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2018.08.531 – volume: 144 start-page: 444 year: 2012 ident: 10.1016/j.jtho.2019.05.037_bib25 article-title: Surgery for oligometastatic non-small cell lung cancer: long-term results from a single center experience publication-title: J Thorac Cardiovasc Surg doi: 10.1016/j.jtcvs.2012.05.051 – volume: 16 start-page: 908 year: 2016 ident: 10.1016/j.jtho.2019.05.037_bib19 article-title: Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies publication-title: BMC Cancer doi: 10.1186/s12885-016-2952-3 – volume: 4 year: 2018 ident: 10.1016/j.jtho.2019.05.037_bib5 article-title: Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2017.3501 – volume: 16 start-page: 348 year: 2016 ident: 10.1016/j.jtho.2019.05.037_bib29 article-title: Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer publication-title: BMC Cancer doi: 10.1186/s12885-016-2379-x – volume: 77 start-page: 216 issue: suppl 2 year: 2015 ident: 10.1016/j.jtho.2019.05.037_bib16 article-title: Surgical treatment of extrapulmonary oligometastatic non-small cell lung cancer publication-title: Indian J Surg doi: 10.1007/s12262-012-0771-6 – volume: 7 start-page: 1547 year: 2012 ident: 10.1016/j.jtho.2019.05.037_bib26 article-title: Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450) publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e318262caf6 – volume: 82 start-page: 95 year: 2013 ident: 10.1016/j.jtho.2019.05.037_bib28 article-title: Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors publication-title: Lung Cancer doi: 10.1016/j.lungcan.2013.07.023 – volume: 29 start-page: iv192 issue: suppl 4 year: 2018 ident: 10.1016/j.jtho.2019.05.037_bib1 article-title: Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol doi: 10.1093/annonc/mdy275 – volume: 84 start-page: e61 year: 2012 ident: 10.1016/j.jtho.2019.05.037_bib13 article-title: Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2012.02.054 – volume: 90 start-page: 850 year: 2014 ident: 10.1016/j.jtho.2019.05.037_bib18 article-title: Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2014.07.012 – volume: 5 start-page: e355 year: 2015 ident: 10.1016/j.jtho.2019.05.037_bib21 article-title: Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung cancer: a hypothesis-generating study publication-title: Pract Radiat Oncol doi: 10.1016/j.prro.2014.11.006 – volume: 7 start-page: 670 year: 2016 ident: 10.1016/j.jtho.2019.05.037_bib17 article-title: Clinical outcome of node-negative oligometastatic non-small cell lung cancer publication-title: Thorac Cancer doi: 10.1111/1759-7714.12386 – volume: 91 start-page: 153 year: 2018 ident: 10.1016/j.jtho.2019.05.037_bib30 article-title: Strategies and technical challenges for imaging oligometastatic disease: recommendations from the European Organisation for Research and Treatment of Cancer imaging group publication-title: Eur J Cancer doi: 10.1016/j.ejca.2017.12.012 – volume: 13 start-page: S446 year: 2018 ident: 10.1016/j.jtho.2019.05.037_bib8 article-title: MA25.02 Searching for a definition of synchronous oligometastatic (sOM)-NSCLC: a consensus from thoracic oncology experts publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2018.08.530 – volume: 78 start-page: 234 year: 2012 ident: 10.1016/j.jtho.2019.05.037_bib24 article-title: Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage publication-title: Lung Cancer Amst Neth doi: 10.1016/j.lungcan.2012.09.011 – volume: 9 start-page: 2235 year: 2017 ident: 10.1016/j.jtho.2019.05.037_bib3 article-title: Role of consolidative stereotactic ablative radiotherapy in patients with oligometastatic non-small cell lung cancer publication-title: J Thorac Dis doi: 10.21037/jtd.2017.06.133 – ident: 10.1016/j.jtho.2019.05.037_bib4 – reference: 31757373 - J Thorac Oncol. 2019 Dec;14(12):2042-2045 |
| SSID | ssj0045048 |
| Score | 2.5018923 |
| SecondaryResourceType | review_article |
| Snippet | Synchronous oligometastatic (sOM) disease is an oncological concept characterized by a limited cancer burden. Patients with oligometastasis could potentially... INTRODUCTION:Synchronous oligometastatic (sOM) disease is an oncological concept characterized by a limited cancer burden. Patients with oligometastasis could... Introduction: Synchronous oligometastatic (sOM) disease is an oncological concept characterized by a limited cancer burden. Patients with oligometastasis could... |
| SourceID | hal proquest pubmed crossref wolterskluwer elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2053 |
| SubjectTerms | Life Sciences NSCLC Oligometastatic disease definition Synchronous Systematic review |
| Title | Defining Synchronous Oligometastatic Non–Small Cell Lung Cancer: A Systematic Review |
| URI | https://dx.doi.org/10.1016/j.jtho.2019.05.037 https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=01243894-201912000-00006 https://www.ncbi.nlm.nih.gov/pubmed/31195177 https://www.proquest.com/docview/2263338958 https://hal.science/hal-03489080 |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLa6TkIghLgNyk0B8VYFJY7TJLyVbVCxrkh0G3uzHMehKV2CSlsET_wH_gC_jV_COXGSpu2YYKoUVc7d54v9HZ8bIc-BQnsikpYJgIlN5mMOSE9Qs6OUH0gZwayAFt3DQad3zN6euqeNxq-a19J8Fr6Q38-NK7mMVKEN5IpRsv8h2eqi0AD_Qb6wBQnD9p9kvKfivL5De_gtlZjlFv1Z302Sj9mZmgmMFUpkewDkrvBocIZnaInexfW6_hwN_ijzqY5OHy5zOtcMBpu8dTYC1Eg4Kkvlypr8m0SMzb5a5JWLEGKwG-3wr-j5R2CpcZUtmTQo7fN8KjyBSWuaVIgbZIvSQjRMJotE1Fcq7GDN66MKoVnx8AQ-0zFBr9KrCmrZZju6xFM1TLM6HGl90LV0vuFiAqeWTu--MTnodYox9NwIwz7tIM_ZqnPOrCXdHuIj4FMBv0VTsrdFtikoIrRJtrsH7z8clLM9c628Qlv1GkVglvYhXL_T38jP1gi9cDdVnGvk-tcMvSa-fMqDJmrU5-gmuVHI3uhqAN4iDZXeJlcOC6-MO-SkxKFRw6GxhkMDcPj7x88cgQYi0EAEGhqBL42uscSfofF3lxy_3j_a7ZlFvQ5TMi8AiUWRA79OTGPhhyIATduxIhoo5gsGiqvvRkEcC-BMVqDCCGiR7cS2HQFDDl0Vhc4OaaZZqu4Tw40kVTD9AN91mBQ0kDQSLMZ0kiGLpdcidtmRXBbJ7LGmyoSXXotjjp3PsfO55XLo_BZpV-d81qlcLjzaLeXDCzKqSSYHOF143jMQZnUDzN7e6_Y5tlkOjIWgoS3sFnlayprDcI42OpEqkA0HbchxQIlw_Ra5p0FQXcvB9Iy2B7cwV1DBdcg0B67J4FRm4uPYZc4Iq_Pgkq_ykFxdfsaPSHM2navHQMFn4ZPiK_gDSwbX1Q |
| linkProvider | Library Specific Holdings |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Defining+Synchronous+Oligometastatic+Non%E2%80%93Small+Cell+Lung+Cancer%3A+A+Systematic+Review&rft.jtitle=Journal+of+thoracic+oncology&rft.au=Giaj-Levra%2C+Niccol%C3%B2&rft.au=Giaj-Levra%2C+Matteo&rft.au=Durieux%2C+Valerie&rft.au=Novello%2C+Silvia&rft.date=2019-12-01&rft.pub=Elsevier+Inc&rft.issn=1556-0864&rft.eissn=1556-1380&rft.volume=14&rft.issue=12&rft.spage=2053&rft.epage=2061&rft_id=info:doi/10.1016%2Fj.jtho.2019.05.037&rft.externalDocID=S1556086419304587 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1556-0864&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1556-0864&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1556-0864&client=summon |